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Purpose of review 
To date 16 genes have been associated with arrhythmogenic cardiomyopathy (ACM). 
Mutations in these genes can lead to a broad spectrum of phenotypic expression ranging from 
disease affecting predominantly the right or left ventricle, to bi-ventricular subtypes. 
Understanding the genetic causes of arrhythmogenic cardiomyopathy is important in diagnosis 
and management of the disorder. This review summarizes recent advances in molecular 
genetics and discusses the application of next generation sequencing technology in genetic 
testing in ACM. 
Recent findings 
  
Use of next generation sequencing methods has resulted in the identification of novel causative 
variants and genes for arrhythmogenic cardiomyopathy. The involvement of FLNC in ACM 
demonstrates the genetic overlap between arrhythmogenic cardiomyopathy and other types of 
cardiomyopathy. Putative pathogenic variants have been detected in CDH2, the gene encoding 
cadherin 2, a protein involved in cell adhesion. Large genomic rearrangements in desmosome 
genes have been systematically investigated in a cohort of ACM patients. 
Summary 
Recent studies have identified novel causes of arrhythmogenic cardiomyopathy providing new 
insights into the genetic spectrum of the disease and highlighting an overlapping phenotype 
between arrhythmogenic cardiomyopathy and dilated cardiomyopathy. Next generation 
sequencing is a useful tool for research and genetic diagnostic screening but interpretation of 
identified sequence variants requires caution and should be performed in specialized centers. 
 
Keywords 
Arrhythmogenic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, genetics, 
mutations, next generation sequencing 
 
INTRODUCTION 
Arrhythmogenic cardiomyopathy (ACM) is a rare, primary heart muscle disorder, presenting 
with increased risk for ventricular arrhythmias and sudden cardiac death. Histologically, ACM 
is characterized by loss of myocardial tissue and its replacement by fibrofatty tissue. [1] ACM 
affects approximately 1 in 2000 to 5000 individuals and is considered one of the major causes 
  
of arrhythmic sudden cardiac death in the young and athletes. [1] It is typically inherited as an 
autosomal dominant disorder but a small number of recessive cases are also known. [2*] 
The disorder was originally termed “arrhythmogenic right ventricular dysplasia” 
(ARVD) suggesting the dysplastic nature of the disease. [3] ACM patients have a structurally 
normal heart at birth and develop the cardiomyopathy changes later on. It was later named 
“arrhythmogenic right ventricular cardiomyopathy” (ARVC) because it was believed that the 
disease predominantly affects the right ventricle. [1] This is only true for classic disease 
subtypes and the recognition of other forms, i.e. predominant left-sided or bi-ventricular 
cardiomyopathy, has led to the adoption of the broader term “arrhythmogenic 
cardiomyopathy”. 
The purpose of this review is to aid physicians to better understand the genetic basis of 
ACM, review publications in the past year and highlight recent findings that increase our 
knowledge of the genetic causes related to development of this complex disease, and discuss 
the use of next generation sequencing in the genetic diagnosis of ACM. 
 
GENETIC BASIS 
Known genes linked to ACM 
The key to the discovery of the genetic causes of ACM was its association with palmoplantar 
keratoderma and woolly hair in the description of Naxos Disease, named after the Greek island, 
where the first observed families resided. [4] The syndrome is inherited in an autosomal 
recessive manner with full penetrance by adolescence that facilitated genetic linkage analysis 
and identification of homozygosity for a two-nucleotide deletion (2157del2) in plakoglobin 
(JUP) as the underlying genetic cause. [5]  
  
Soon after, mutations in other genes encoding main components of the desmosome 
were found to cause ACM, including desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-
2 (DSG2) and desmocollin-2 (DSC2). [6-9] Desmosomes are complex structures consisting of 
proteins and are responsible for cell adhesion and signalling. [10] Thus, abnormalities in 
desmosome structure were justifiably considered to have a key role in ACM pathogenesis and 
the classic form of the disease presenting with right ventricular cardiomyopathy was considered 
a “disease of the desmosome”. [11] Approximately 30-50% of ACM patients carry a 
pathogenic sequence variant in one of these key desmosome genes (Table 1). In the majority 
of cases inheritance is in an autosomal dominant manner with incomplete penetrance and 
variable expressivity. [22]  
Mutations in other, non-desmosomal genes have been have been found in families with 
ACM (Table 1). These include: transforming growth factor β3 (TGF-β3); transmembrane 
protein 43 (TMEM43); alpha T-catenin (CTNNA3); titin (TTN); lamin A/C (LMNA); 
phospholamban (PLN) and desmin (DES). [12, 14,15, 17-20] Such findings in genes previously 
linked to other forms of cardiomyopathies, represent an overlap between ACM and dilated 
cardiomyopathy (DCM) both at the clinical and genetic level. Finally, it is also worth noting 
that mutations in the cardiac ryanodine receptor 2 (RYR2) gene have also been reported in ACM 
[23] but it is now recognised that the observed phenotype is catecholamine-induced ventricular 
tachycardia rather than ACM and this gene is no longer considered as ACM causing. 
Genetic studies can identify a causative mutation in up to 60% of ACM cases. In the 
largest study of ACM patients and family members to date, 37% of cases were negative for 
mutations in desmosome genes, TMEM43 or PLN. [24] It is postulated that gene-negative ACM 
cases could possibly harbour mutations in unidentified genes or non-coding parts of the genome 
or have large deletions/duplications. It is also possible that disease in those individuals could 
  
be the result of a combination of unknown low-penetrance genetic variants and environmental 
factors which would point to an oligogenic form of ACM, as reported in human HCM. (25) 
New genes linked to ACM 
In the last year three new genes have been implicated in the pathogenesis of ACM. Ortiz-Genga 
et al. [16**] used next generation sequencing to screen 2,877 patients with inherited 
cardiovascular disease. They identified 23 truncating mutations in the filamin C (FLNC) gene 
in probands with dilated and left-dominant arrhythmogenic cardiomyopathy. Filamin C is 
expressed in striated muscle where it interacts with the actin cytoskeleton and other sarcomere 
proteins providing stability and signalling functions. [26] FLNC mutations have been 
previously associated with dilated cardiomyopathy [27] but the study by Ortiz-Genga et al. 
[16**] clearly demonstrated how ACM and arrhythmogenic forms of DCM overlap in the 
clinical and genetic level.  
 Using whole exome sequencing two groups independently identified cadherin 2 
(CDH2) as a novel ACM gene. [13*, 28] The number of ACM patients included in those studies 
was relatively small (single patient in one and 73 genotype-negative probands in the other) and 
only two CDH2 putatively disease-causing variants were detected in total. However, cadherin 
2 is a biologically plausible candidate gene for ACM as it plays an important role in cell 
adhesion. [29] Along with alpha T-catenin, a gene already implicated in ACM, cadherin 2 is 
expressed in the area composita, a specialized region of the intercalated discs which connect 
cardiomyocytes to one another. 
 Interestingly, a recent study has proposed that the voltage-gated sodium channel subunit 
alpha Nav1.5 (SCN5A) gene is associated with ACM. [21*] The authors detected a putatively 
pathogenic SCN5A sequence variant in 5/281 patients (1.8%) fulfilling diagnostic criteria for 
arrhythmogenic right ventricular cardiomyopathy. Those variants were associated with 
prolonged QRS duration and their carriers had major structural abnormalities on cardiac 
  
imaging. [21*] Furthermore, based on functional studies performed on one variant 
(Arg1898His), the authors suggest that Nav1.5 is in a functional complex with adhesion 
molecules such as N-cadherin. This would potentially indicate that Nav1.5 dysfunction causes 
ACM via non-canonical mechanisms. If validated in larger studies, these findings could have 
important implications on our understanding of the pathogenesis of ACM. 
Large genomic rearrangements linked to ACM 
Until recently, copy number variations (CNVs, i.e. large genomic rearrangements such as gross 
deletions, insertions and duplications) in the PKP2 gene have been reported in case reports as 
the cause of arrhythmogenic cardiomyopathy. [30,31] Pilichou et al. [32**] adopted a 
systematic approach to determine the prevalence of CNVs in the five key desmosome genes in 
ACM patients negative for point mutations in these genes. Investigation of 160 index cases 
revealed 11 CNVs (6.9%) in PKP2, but also in DSC2 and DSG2 genes. It should be noted 
however that only 32% of family members carrying the CNV fulfilled the diagnostic criteria. 
Regardless, these results support CNV screening as potential causes of ACM. 
NEXT GENERATION SEQUENCING SCREENING AND ACM 
Recent advances in DNA sequencing techniques have revolutionized cardiovascular genetics 
facilitating rapid, accurate and cost-effective screening of human DNA for variation on the 
whole genome scale. Three different approaches are available: targeted sequencing of specific 
gene panels; whole exome sequencing (WES) and whole genome sequencing. In practice, for 
inherited cardiovascular diseases and in particular for ACM, only the first two methods are 
currently used for diagnostic purposes and research in order to identify known as well as novel 
causative variants and genes. 
 Given the emerging, common genetic causes and overlapping phenotypes amongst 
different types of cardiomyopathy, including ACM, many groups have designed broad targeted 
  
gene panels that include not just ACM-associated genes but also known causative genes for 
other cardiomyopathies. For example, a recent study which identified FLNC as disease-causing 
in ACM, used a panel of 213 genes related to inherited cardiovascular diseases and sudden 
death [16**], whilst Hertz et al. [33] screened 100 genes previously associated with inherited 
cardiomyopathies and channelopathies. In another study of a small cohort of 14 patients, 
analysis focused on 96 known genes and found potentially pathogenic variants in 64% of cases. 
[34*]  
However, the targeted gene approach can only detect variants in known genes and 
therefore patients with no identified mutation must be screened again by WES which 
theoretically covers the entire human exome. WES has been successful in finding new ACM 
genes [13*] and is mainly used for research rather than diagnostic screening. This is mainly 
due to the serious difficulties in interpretation of WES genetic data in general.  Classification 
of genetic variants according to their predicted pathogenicity remains challenging as current 
bioinformatics software used for this purpose lack specificity whilst many rare ACM variants 
are also present in the general population [35, 36], a fact that raises doubts about whether they 
can be genuinely disease-causing. Such variants are currently classified as “variants of 
unknown significance” (VUS). Consequently, interpretation of rare and/or novel genetic 
variants in ACM cases should be performed with caution as their pathogenicity cannot be fully 
ascertained. 
 
CHALLENGES IN GENETIC TESTING 
The role of genetic testing in ACM is fundamental in identifying a pathogenic mutation in an 
index case and subsequently determining the potential risk in their family members. So much 
so that the presence of a pathogenic mutation has been classified as a major criterion in the 
2010 modification of the Task Force criteria for the diagnosis of ACM. [37]  
  
However, utilization of genetic results in daily clinical practice is hindered by a number 
of factors. The main ones include: ACM presents with incomplete, age-related penetrance and 
variable phenotypic expression; a proportion of cases carry more than one variant in the same 
or different genes; as described earlier in this review, variants detected in ACM cases have also 
been found in apparently healthy individuals; and, finally, our incomplete understanding of the 
functional significance of sequence variants obtained by genetic screening.  As other cardiac 
disorders can mimic certain phenotypic features of ACM, in some index cases gene testing 
should not be used as the only diagnostic tool. 
These limitations highlight the necessity to perform genetic testing and review the 
resulting genetic data in expert cardiovascular centers. 
 
PATHOGENESIS 
Within the heart, desmosome proteins are known to be expressed primarily in cardiac 
myocytes. The deletion of the Dsp gene in cardiac myocytes leads to cardiac dysfunction, 
cardiac arrhythmias, premature death, and fibro-adipogenesis (38). Research over several years 
in mouse models of ACM has provided insights into the cellular origin and mechanisms of 
ACM. Recent studies have shown that cells other than cardiac myocytes contribute to the 
pathogenesis of ACM (39-41). Specifically, fibroadipocyte progenitor cells, marked by the 
expression of platelet derived growth factor alpha and other markers, were shown to express 
desmosome proteins and upon deletion of Dsp differentiate to fibroadipocytes in ACM (40). 
Furthermore, deletion of desmoplakin in cells of the cardiac conduction system and skin 
keratinocytes, marked by the expression of chondroitin sulfate proteoglycan 4 leads to cardiac 
arrhythmias, palmoplantar keratosis, and alopecia, as observed in Naxos disease (41).  
Mechanistic studies using these models identified a critical role of the canonical WNT and 
Hippo pathways in fibroadipogenesis in ACM (38, 40, 42-44).  Taken together these findings 
  
provide plausible mechanisms and expand the current view of the pathogenesis of ACM, 
supporting a multicellular origin of its phenotypes.  
GENOTYPE-PHENOTYPE CORRELATIONS 
Studies of patients with ACM have shown high genetic heterogeneity and limited genotype-
phenotype correlations. [45] Disease expression can vary significantly amongst ACM patients, 
even in those harbouring mutations in the same gene or carrying the same mutation. [46] A 
large study of over 1,000 ACM patients and family members found no statistically significant 
difference in clinical characteristics and outcomes between probands with and without 
mutations, as well as those with familial and non-familial disease. [24] However, patients with 
multiple mutations (homozygotes, compound heterozygotes, or digenic mutation carriers) 
generally exhibit a more severe phenotype [47, 48] and the presence of multiple desmosome 
gene variants is a significant risk factor for major arrhythmic events and sudden cardiac death. 
[48] In addition, patients with multiple variants have been demonstrated to develop 
significantly earlier onset of symptoms and occurrence of sustained ventricular arrhythmias. 
[49] 
 A recent meta-analysis of eleven genotype-phenotype relationship studies revealed that 
mutations in genes encoding desmosome proteins were associated with an early age of onset 
of the disease, presence of T wave inversion in the precordial leads, and a family history of 
ACM. [50] On the other hand, presence and severity of cardiac structural abnormalities, epsilon 
wave, and ventricular tachycardia were similar in those with and without mutations in genes 
encoding desmosome proteins. Finally, Castelletti et al. [51] compared groups of ACM patients 
carrying missense and non-missense mutations in desmoplakin. Non-missense DSP mutations 
were particularly associated with left-dominant forms of the disease as left ventricular 
dysfunction and left ventricular structural abnormalities were significantly more common in 
patients with non-missense mutations compared to those with missense variants. [51]   
  
 
CONCLUSION 
ACM is an inherited cardiomyopathy characterized by genetic heterogeneity, incomplete 
penetrance and variable phenotypic expression. Mutations in known ACM genes only account 
approximately for 60% of patients suggesting that other, yet unidentified, genetic defects could 
be the cause of the condition in the remaining cases.  
Recent studies expanded the genetic spectrum of ACM by implicating a further 3 genes, 
FLNC, CDH2 and SCN5A, in the pathogenesis of the disorder. The discovery of ACM-causing 
mutations in FLNC, a gene causative in other cardiomyopathies too, established beyond doubt 
that ACM shares genetic background and clinical presentation with arrhythmogenic forms of 
DCM. The studies on CDH2 are in agreement with current knowledge that defects in cell 
adhesion genes can lead to ACM. The role of SCN5A in ACM is still not fully understood and 
studies in larger patient cohorts are required in order to elucidate how mutations in this gene 
can cause ACM. 
Genetic testing plays an important role in detecting potentially pathogenic mutations in 
probands and identifying relatives at risk of developing the disorder. In that respect next 
generation sequencing methods are a useful tool in investigating the genetic basis of ACM but 
interpretation of genetic results requires specialized knowledge and expertise.  
 
 
KEY POINTS 
 ACM is a rare primary myocardial disease and an important cause of sudden cardiac 
death in the young. 
  
 Sixteen genes have been implicated in ACM but mutations in those only account for 
approximately 60% of cases. 
 Recent discoveries of new causative genes such as FLNC have broadened the genetic 
spectrum of the disease and highlighted the genetic and phenotypic overlap between 
ACM and other types of cardiomyopathy, particularly DCM. 
 There is evidence of genotype-phenotype correlations with limited clinical utility at 
present. 
 Interpretation of genetic data obtained by next generation sequencing remains 
challenging and should be performed in expert centers. 
 
Acknowledgements 
This work was funded by Fondation Leducq Transatlantic Networks of Excellence Program: 
GRANT no 14 CVD 03 and supported by the National Institute for Health Research University 
College London Hospitals Biomedical Research Centre. 
 
Conflicts of interest 
There are no conflicts of interest 
 
REFERENCES AND RECOMMENDED READING 
1. Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right ventricular 
cardiomyopathy. Lancet 2009; 373:1289-1300. 
  
2. Hoorntje ET, te Rijdt WP, James CA, et al. Arrhythmogenic cardiomyopathy: 
pathology, genetics, and concepts in pathogenesis. Cardiovasc Res 2017; 113:1521-
1531. 
* This manuscript provides a thorough review of the pathogenic mechanisms in ACM. 
3. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 
24 adult cases. Circulation 1982; 65:384-398.  
4. Protonotarios N, Tsatsopoulou A, Patsourakos P, et al. Cardiac abnormalities in 
familial palmoplantar keratosis. Br Heart J 1986; 56:321-326. 
5. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin 
in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma 
and woolly hair (Naxos disease). Lancet 2000; 355:2119-2124.  
6. Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain 
binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular 
cardiomyopathy. Am J Hum Genet 2002; 71:1200-1206. 
7. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-
2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004; 
36:1162-1164. 
8. Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with 
arrhythmogenic right ventricular cardiomyopathy. Circulation 2006; 113:1171-1179. 
9. Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular 
dysplasia/cardiomyopathy associated with mutations in the desmosomal gene 
desmocollin-2. Am J Hum Genet 2006; 79:978-984.  
10. Huber O. Structure and function of desmosomal proteins and their role in development 
and disease. Cell Mol Life Sci 2003; 60:1872-1890. 
  
11. Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of right ventricular 
cardiomyopathy. J Cardiovasc Electrophysiol 2005; 16:927-935. 
12. van Hengel J, Calore M, Bauce B, et al. Mutations in the area composita protein alphaT-
catenin are associated with arrhythmogenic right ventricular cardiomyopathy. Eur 
Heart J 2013; 34:201-210.  
13. Mayosi BM, Fish M, Shaboodien G, et al. Identification of cadherin 2 (CDH2) 
mutations in arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 
2017; 10:e001605. 
 This study identified mutations in CDH2 further supporting the view that defects in cell 
adhesion genes cause ACM. 
14. Merner ND, Hodgkinson KA, Haywood AF, et al. Arrhythmogenic right ventricular 
cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a 
missense mutation in the TMEM43 gene. Am J Hum Genet 2008; 82:809-821. 
15. Taylor M, Graw S, Sinagra G, et al. Genetic variation in titin in arrhythmogenic right 
ventricular cardiomyopathy-overlap syndromes. Circulation 2011; 124:876-885. 
16. Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC mutations are 
associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll 
Cardiol 2016; 68:2440-2451. 
** This study identified FLNC as a disease-causing gene in ACM and highlighted the 
genetic and overlap between ACM and DCM. 
17. Quarta G, Syrris P, Ashworth M, et al. Mutations in the Lamin A/C gene mimic 
arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2012; 33:1128-1136. 
18. Beffagna G, Occhi G, Nava A, et al. Regulatory mutations in transforming growth 
factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. 
Cardiovasc Res 2005; 65:366-373. 
  
19. van der Zwaag PA, van Rijsingen IA, Asimaki A, et al. Phospholamban R14del 
mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right 
ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic 
cardiomyopathy. Eur J Heart Fail 2012; 14:1199-1207. 
20. van Tintelen JP, Van Gelder IC, Asimaki A, et al. Severe cardiac phenotype with right 
ventricular predominance in a large cohort of patients with a single missense mutation 
in the DES gene. Heart Rhythm 2009; 6:1574-1583. 
21. Te Riele AS, Agullo-Pascual E, James CA, et al. Multilevel analyses of SCN5A 
mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-
canonical mechanisms for disease pathogenesis. Cardiovasc Res 2017; 113:102-111. 
* First study to implicate SCN5A in ACM.Tiso N, Stephan DA, Nava A, et al. 
Identification of mutations in the cardiac ryanodine receptor gene in families affected 
with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol 
Genet 2001; 10:189-194. 
22. Corrado D, Basso C, Pilichou K, et al. Molecular biology and clinical management of 
arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart 2011; 97:530-539. 
23.  Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine 
receptor gene in families affected with arrhythmogenic right ventricular 
cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10:189-194. 
24. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-
up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy 
patients and family members. Circ Cardiovasc Genet 2015; 8:437-446. 
25. Li L, Bainbridge MN, Tan Y, Willerson JT, et al. A Potential Oligogenic Etiology of 
Hypertrophic Cardiomyopathy: A Classic Single-Gene Disorder. Circ Res. 2017; 
7:1084-1090 
  
26. Fürst DO, Goldfarb LG, Kley RA, et al. Filamin C-related myopathies: pathology and 
mechanisms. Acta Neuropathol 2013; 125:33-46. 
27. Begay RL, Tharp CA, Martin A, et al. FLNC gene splice mutations cause dilated 
cardiomyopathy. JACC Basic Transl Sci 2016; 1:344-359. 
28. Turkowski KL, Tester DJ, Bos JM, et al. Whole exome sequencing with genomic 
triangulation implicates CDH2-encoded N-cadherin as a novel pathogenic substrate for 
arrhythmogenic cardiomyopathy. Congenit Heart Dis 2017; 12:226-235. 
29. Sheikh F, Ross RS, Chen J. Cell-cell connection to cardiac disease. Trends Cardiovasc 
Med 2009; 19:182–190. 
30. Roberts JD, Herkert JC, Rutberg J, et al. Detection of genomic deletions of PKP2 in 
arrhythmogenic right ventricular cardiomyopathy. Clin Genet 2013; 83:452-456. 
31. Li Mura IE, Bauce B, Nava A, et al. Identification of a PKP2 gene deletion in a family 
with arrhythmogenic right ventricular cardiomyopathy. Eur J Hum Genet 2013; 
21:1226-1231. 
32. Pilichou K, Lazzarini E, Rigato I, et al. Large genomic rearrangements of desmosomal 
genes in italian arrhythmogenic cardiomyopathy patients. Circ Arrhythm 
Electrophysiol 2017; 10: e005324. 
** First systematic study of desmosome gene CNVs in ACM. 
33. Hertz CL, Christiansen SL, Ferrero-Miliani L, et al. Next-generation sequencing of 100 
candidate genes in young victims of suspected sudden cardiac death with structural 
abnormalities of the heart. Int J Legal Med 2016; 130:91-102. 
34. Medeiros-Domingo A, Saguner AM, Magyar I, et al. Arrhythmogenic right ventricular 
cardiomyopathy: implications of next-generation sequencing in appropriate diagnosis. 
Europace 2017; 19:1063-1069. 
*  This study uses WES for screening of ACM cases. 
  
35. Andreasen C, Nielsen JB, Refsgaard L, et al. New population-based exome data are 
questioning the pathogenicity of previously cardiomyopathy-associated genetic 
variants. Eur J Hum Genet 2013; 21:918-928. 
36. Lahtinen AM, Lehtonen E, Marjamaa A, et al. Population-prevalent desmosomal 
mutations predisposing to arrhythmogenic right ventricular cardiomyopathy. Heart 
Rhythm 2011; 8:1214-1221.  
37. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right 
ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. 
Circulation 2010; 121:1533-1541. 
38. Garcia-Gras E, Lombardi R, Giocondo  MJ, et al. Suppression of canonical Wnt/beta-
catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic 
right ventricular cardiomyopathy. J Clin Invest. 2006; 116:2012–2021. 
39. Sommariva  E, Brambilla  S, Carbucicchio  C, et al. Cardiac mesenchymal stromal 
cells are a source of adipocytes in arrhythmogenic cardiomyopathy. Eur Heart J. 2016; 
37:1835–1846. 
40. Lombardi R, Chen SN, Ruggiero  A, et al. Cardiac fibro-adipocyte progenitors express 
desmosome proteins and preferentially differentiate to adipocytes upon deletion of the 
desmoplakin gene. Circ Res. 2016; 119:41–54.  
41. Karmouch J, Zhou QQ, Miyake CY, et al. Distinct Cellular Basis for Early Cardiac 
Arrhythmias, the Cardinal Manifestation of Arrhythmogenic Cardiomyopathy, and the 
Skin Phenotype of Cardiocutaneous Syndromes. 2017; 121:1346-1359. 
42. Lombardi R, Dong J, Rodriguez G, et al. Genetic fate mapping identifies second heart 
field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular 
cardiomyopathy. 2009; 104:1076-1084. 
  
43. Lombardi R, da Graca Cabreira-Hansen M, Bell A, et al. Nuclear plakoglobin is 
essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic 
right ventricular cardiomyopathy. 2011; 109:1342-53. 
44. Chen  SN,  Gurha  P, Lombardi  R, et al. The hippo pathway is activated and is a causal 
mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ Res. 2014; 
114:454–468. 
45. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management 
of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll 
Cardiol 2007; 50:1813-1821. 
46. Syrris P, Ward D, Asimaki A, et al. Desmoglein-2 mutations in arrhythmogenic right 
ventricular cardiomyopathy: a genotype-phenotype characterization of familial disease. 
Eur Heart J 2007; 28:581-588. 
47. Xu T, Yang Z, Vatta M, et al. Compound and digenic heterozygosity contributes to 
arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2010; 55:587-
597. 
48. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts 
lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related 
arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013; 6:533-
542. 
49. Bhonsale A, Groeneweg JA, James CA, et al. Impact of genotype on clinical course in 
arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation 
carriers. Eur Heart J 2015; 36:847-855. 
50. Xu Z, Zhu W, Wang C, et al. Genotype-phenotype relationship in patients with 
arrhythmogenic right ventricular cardiomyopathy caused by desmosomal gene 
mutations: A systematic review and meta-analysis. Sci Rep 2017; 7:41387. 
  
51. Castelletti S, Vischer AS, Syrris P, et al. Desmoplakin missense and non-missense 
mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype 
correlation. Int J Cardiol 2017; 249:268-273. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. Genes implicated in ACM 
Gene Protein Chromosomal 
location 
Estimated 
prevalence 
(%) 
References 
Known ACM genes coding for desmosome proteins  
PKP2 Plakophilin-2 12p11.21 30-40 [7] 
DSP Desmoplakin 6p24.3 10-15 [6] 
DSG2 Desmoglein-2 18q12.1 3-8 [8] 
DSC2 Desmocollin-2 18q12.1 1-5 [9] 
JUP Plakoglobin 17q21.2 <1 [5] 
 
Other potential genes in ACM    
CTNNA3 Alpha T-catenin 10q21.3 <1 [12] 
CDH2 N-Cadherin 18q12.1 <1 [13*] 
TMEM43 Transmembrane protein 43 3p25.1 <1 [14] 
TTN Titin 2q31.2 <1 [15] 
FLNC Filamin C 7q32.1 <1 [16**] 
LMNA Lamin A/C 1q22 <1 [17] 
TGF-β3 Transforming growth factor β3 14q24.3 <1 [18] 
PLN Phospholamban 6q22.31 <1 [19] 
DES Desmin 2q35 <1 [20] 
SCN5A Voltage-gated sodium channel 
subunit alpha Nav1.5 
 
3p22.2 
 
<1 
 
[21*] 
 
 
 
 
 
 
